Communication, Dissemination & Outreach Plan

DKFZ strongly supports and help researchers engage in science outreach activities via several means, so I will take courses on communicating science (e.g. Science Communication & Outreach (training.institut-curie.org/courses/), Lets talk science (www.linkedin.com/company/let%27s-talk-science)) to convey science to the general public and other target groups. As a Marie Sklodowska Curie Fellow I will actively engage and provide the public with insights into my research via science outreach activities organized by DKFZ (e.g. open seminars, collaboration with clinicians,internal research team meetings) and will volunteer in Teachers + Scientists which is aimed to educate teachers thereby, school students the research and advancements in cancer prevention and immunotherapy (www.dkfz.de/en/immuntherapie- immunpraevention/groups/outreach.html). I will also promote science to encourageyoung aspirants through science fairs such as Berlin Science week (https://berlinscienceweek.com/). DKFZ works in close association with the University Clinic Heidelberg. I would avail this opportunity to participate to meet patientsand make them aware of new research in cancer therapy and management through oral and poster presentations and answering to their questions. During the project, the experimental outcomes will be discussed in regular internal research team meetings to provide updates on the progress of the project and receive constructive feedback andsuggestions from team members. All the single-cell transcriptomics data will be made available to the wide public through a database (e.g. scRNASeqDB (https://bioinfo.uth.edu/scrnaseqdb/)). Research findings from this project willbe disseminated through presentations at national and international meetings (ASH (American Society of Hematology) and EHA (European Hematology Association) meetings, iwCLL (International Workshop on CLL). Since the proposed project addresses important questions and has high potential for translation, the results will be published in high-impact journals (Immunity, Leukemia), in which the Martina Seiffert laboratory has published recently. The publications will be open access in accordance with the Horizon Europe open access policy. The present project aims to unravel the negative effects of IL4i1 on DC functions relevant in DC vaccines and investigates to establish IL4i1-/- DCs as potent candidates in DC vaccines to treat CLL. The proposed research, although has great translational potency, is an early discovery stage of the commercialization pipeline. Any intellectual property, material transfer agreements, issues around patent protected procedures and material related to this project will be duly discussed and managed through the Innovation Management Office of DKFZ.